Greig Estabrooks, general manager of Valneva, talks partnership opportunities for the French-Austrian pure-play vaccine company in Canada, its exciting pipeline, and how he encourages his global R&D colleagues to consider conducting clinical trials for their pipeline products in Canada in order to leverage the country’s great infrastructure and significant human capital.
Greig, you have been with Valneva Canada since its beginnings in the country in 2015. How has the company evolved over the last two years?
"Our vision is to become the leading travel vaccine company in Canada by being the preferred partner supporting health care providers in offering convenient and consistent high-quality travel health vaccines to patients and consumers."
